Odanacatib in postmenopausal women with low bone mineral density: A review of current clinical evidence

Therapeutic Advances in Musculoskeletal Disease

Volumn 5, Issue 4, 2013, Pages 199-209

  Zerbini, Cristiano A F ^a   Mcclung, Michael R ^b  

^a HOSPITAL HELIÓPOLIS   (Brazil)

^b OREGON OSTEOPOROSIS CENTER   (United States)

Author keywords

animal models; bone demineralization; bone density conservation agents; bone remodeling; cathepsin K; osteoporosis postmenopausal; pathologic

Indexed keywords

ALENDRONIC ACID; AMINO TERMINAL TELOPEPTIDE; ANABOLIC AGENT; ATORVASTATIN; BALICATIB; BISPHOSPHONIC ACID DERIVATIVE; CARBOXY TERMINAL TELOPEPTIDE; CATHEPSIN K; CATHEPSIN K INHIBITOR; COLLAGEN TYPE 1; DENOSUMAB; HYDROXYAPATITE; IBUPROFEN; INTERLEUKIN 1; INTERLEUKIN 17; INTERLEUKIN 6; L 235; ODANACATIB; ONO 5443; OSTEOCLAST DIFFERENTIATION FACTOR; PARACETAMOL; PARATHYROID HORMONE; PARATHYROID HORMONE[1-34]; PLACEBO; PROCOLLAGEN C PROTEINASE; RELACATIB; TRANSCRIPTION FACTOR PAX5; TUMOR NECROSIS FACTOR; UNCLASSIFIED DRUG; UNINDEXED DRUG; VITAMIN D;

ARTICLE; BONE DENSITY; BONE MASS; BONE MATRIX; BONE METABOLISM; BONE REMODELING; BONE TURNOVER; CATHEPSIN K GENE; CELL FUNCTION; CORTICAL BONE; CORTICAL THICKNESS (BONE); DISEASE ASSOCIATION; DOSE RESPONSE; DRUG ACTIVITY; DRUG SAFETY; DRUG TOLERANCE; ENZYME ACTIVITY; ENZYME INHIBITION; FEMUR NECK; FRACTURE; HUMAN; LOSS OF FUNCTION MUTATION; LUMBAR SPINE; NONHUMAN; OSSIFICATION; OSTEOARTHRITIS; OSTEOBLAST; OSTEOCLAST; OSTEOLYSIS; OSTEOPENIA; OSTEOPOROSIS; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); POSTMENOPAUSE; POSTMENOPAUSE OSTEOPOROSIS; PRIORITY JOURNAL; PROTEIN EXPRESSION; PYCNODYSOSTOSIS; RANDOMIZED CONTROLLED TRIAL (TOPIC); RASH; SCLERODERMA; SKIN TOXICITY; TRABECULAR BONE; TREATMENT DURATION; URINARY TRACT INFECTION;

EID: 84887487997     PISSN: 1759720X     EISSN: 17597218     Source Type: Journal    
DOI: 10.1177/1759720X13490860     Document Type: Article

References (60)

1. Atley L. Mort J. Lalumiere M. Eyre D. (2000) Proteolysis of human bone collagen by cathepsin K: characterization of the cleavage sites generating by crosslinked N-telopeptide neoepitope. Bone 26: 241–247.
2. Balkan W. Martinez A. Fernandez I. Rodriguez M. Pang M. Troen B. (2009) Identification of NFAT binding sites that mediate stimulation of cathepsin K promoter activity by RANK ligand. Gene 446: 90–98.
3. Baron R. Ferrari S. Russell R. (2011) Denosumab and bisphosphonates: different mechanisms of action and effects. Bone 48: 677–692.
4. Black W. Percival M. (2006) The consequences of lysosomotropism on the design of selective cathepsin K inhibitors. ChemBioChem 7: 1525–1535.
5. Body J. Facon T. Coleman R. Lipton A. Geurs F. Fan M. et al. (2006) A study of the biological receptor activator of nuclear factor-kappaB ligand inhibitor, denosumab, in patients with multiple myeloma or bone metastases from breast cancer. Clin Cancer Res 12: 1221–1228.
6. Bone H. Bolognese M. Yuen C. Kendler D. Miller P. Yang Y. et al. (2011 b) Effects of denosumab treatment and discontinuation on bone mineral density and bone turnover markers in postmenopausal women with low bone mass. J Clin Endocrinol Metab 96: 972–980.
7. Bone H. McClung M. Roux C. Recker R. Eisman J. Verbruggen N. et al. (2011 a) Odanacatib, a cathepsin-K inhibitor for osteoporosis: a two-year study in postmenopausal women with low bone density. J Bone Miner Res 25: 937–947.
8. Bossard M. Tomaszek T. Thompson S. Amegadzie B. Hanning C. Jones C. et al. (1996) Proteolytic activity of human osteoclast cathepsin K. Expression, purification, activation, and substrate identification. J Biol Chem 271: 12517–12524.
9. Brixen K. Chapurlat R. Cheung A. Keavney T. Fuerst T. Verbruggen N. et al. (2012) Imaging and finite element analysis of the spine and hip following 2 years of treatment with odanacatib in postmenopausal women. In: Proceedings of IOF-ECCEO12 European Congress on Osteoporosis and Osteoarthritis, Bordeaux, France, 21–24 March 2012.
10. Brubaker K. Vessella R. True L. Thomas R. Corey E. (2003) Cathepsin K mRNA and protein expression in prostate cancer progression. J Bone Miner Res 18: 222–230.
11. Chen W. Yang S. Abe Y. Li M. Wang Y. Shao J. et al. (2007) Novel pycnodysostosis mouse model uncovers cathepsin K function as a potential regulator of osteoclast apoptosis and senescence. Hum Mol Genet 16: 410–423.
12. Costa A. Cusano N. Silva B. Cremers S. Bilezikian J. (2011) Cathepsin K: its skeletal actions and role as a therapeutic target in osteoporosis. Nat Rev Rheumatol 7: 447–456.
13. Cremers S. Pillai G. Papapoulos S. (2005) Pharmacokinetics/pharmacodynamics of bisphosphonates: use for optimisation of intermittent therapy for osteoporosis. Clin Pharmacokinet 44: 551–570.
14. Cusick T. Chen C. Pennypacker B. Pickarski M. Kimmel D. Scott B. et al. (2011) Odanacatib treatment increases hip bone mass and cortical thickness by preserving endocortical bone formation and stimulating periosteal bone formation in the ovariectomized adult rhesus monkey. J Bone Miner Res 27: 509–523.
15. de Papp A. Cheung A. Majumdar S. Brixen K. Chapurlat R. Dardzinski B. et al. (2012) Effects of odanacatib on the distal radius and tibia in postmenopausal women: improvements in cortical geometry and estimated bone strength. In: Proceedings ASBMR 2012, Annual Meeting of the American Society for Bone and Mineral Research, Minneapolis, MN, USA, 12–15 October 2012, abstract 1028.
16. de Villiers T. Bonnick S. Odio A. Palacios S. Chapurlat R. Scott B. et al. (2012) Effects of odanacatib on BMD and overall safety in the treatment of osteoporosis in postmenopausal women previously treated with alendronate. In: Proceedings ASBMR 2012 Annual Meeting of the American Society for Bone and Mineral Research, Minneapolis, MN, USA, 12–15 October 2012, abstract 1027.
17. Desmarais S. Masse F. Percival M. (2009) Pharmacological inhibitors to identify roles of cathepsin K in cell-based studies: a comparison of available tools. Biol Chem 390: 941–948.
18. Eastell R. Nagase S. Ohyama M. Small M. Sawyer J. Boonen S. et al. (2011) Safety and efficacy of the cathepsin K inhibitor ONO-5334 in postmenopausal osteoporosis: the OCEAN study. J Bone Miner Res 26: 1303–1312.
19. Eisman J. Bone H. Hosking D. McClung M. Reid I. Rizzoli R. et al. (2011) Odanacatib in the treatment of postmenopausal women with low bone mineral density: three-year continued therapy and resolution of effect. J Bone Miner Res 26: 242–251.
20. Falgueyret J. Desmarais S. Oballa R. Black W. Cromlish W. Khougaz K. et al. (2005) Lysosomotropism of basic cathepsin K inhibitors contributes to increased cellular potencies against off-target cathepsins and reduced functional selectivity. J Med Chem 48: 7535–7543.
21. Fuller K. Lawrence K. Ross J. Grabowska U. Shiroo M. Samuelsson B. et al. (2008) Cathepsin K inhibitors prevent matrix-derived growth factor degradation by human osteoclasts. Bone 42: 200–211.
22. Garnero P. Borel O. Byrjalsen I. Ferreras M. Drake F. McQueney M. et al. (1998) The collagenolytic activity of cathepsin K is unique among mammalian proteinases. J Biol Chem 273: 32347–32352.
23. Gauthier J. Chauret N. Cromlish W. Desmarais S. Le Duong T. Falgueyret J. et al. (2008) The discovery of odanacatib (MK-0822), a selective inhibitor of cathepsin K. Bioorg Med Chem Lett 18: 923–928.
24. Gelb B. Shi G. Chapman H. Desnick R. (1996) Pycnodysostosis, a lysosomal disease caused by cathepsin K deficiency. Science 273: 1236–1238.
25. Gowen M. Lazner F. Dodds R. Kapadia R. Feild J. Tavaria M. et al. (1999) Cathepsin K knockout mice develop osteopetrosis due to a deficit in matrix degradation but not demineralization. J Bone Miner Res 14: 1654–1663.
26. Harvey N. Dennison E. Cooper C. (2010) Osteoporosis: impact on health and economics. Nat Rev Rheumatol 6: 99–105.
27. Hou W. Li Z. Gordon R. Chan K. Klein M. Levy R. et al. (2001) Cathepsin K is a critical protease in synovial fibroblast mediated collagen degradation. Am J Pathol 159: 2167–2177.
28. Isabel E. Bateman K. Chauret N. Cromlish W. Desmarais S. Le Duong T. et al. (2010) The discovery of MK-0674, an orally bioavailable cathepsin inhibitor. Bioorg Med Chem Lett 20: 887–892.
29. Jerome C. Missbach M. Gamse R. (2011) Balicatib, a cathepsin K inhibitor, stimulates periosteal bone formation in monkeys. Osteoporos Int 22: 3001–3011.
30. Jia J. Yao W. Guan M. Dai W. Shahnazari M. Kar R. et al. (2011) Glucocorticoid dose determines osteocyte cell fate. Faseb J 25: 3366–3376.
31. Kassahun K. Black W. Nicoll-Griffith D. McIntosh I. Chauret N. Day S. et al. (2011) Pharmacokinetics and metabolism in rats, dogs, and monkeys of the cathepsin K inhibitor odanacatib: demethylation of a methylsulfonyl moiety as a major metabolic pathway. Drug Metab Dispos 39: 1079–1087.
32. Kumar S. Dare L. Vasko-Moser J. James I. Blake S. Rickard D. et al. (2007) A highly potent inhibitor of cathepsin K (relacatib) reduces biomarkers of bone resorption both in vitro and in an acute model of elevated bone turnover in vivo in monkeys. Bone 40: 122–131.
33. Langdahl B. Binkley N. Bone H. Gilchrist N. Resch H. Rodriguez Portales J. et al. (2012) Odanacatib in the treatment of postmenopausal women with low bone mineral density: five years of continued therapy in a phase II study. J Bone Miner Res. 27: 2251–2258.
34. Leung P. Pickarski M. Zhuo Y. Masarachia P. Duong L. (2011) The effects of the cathepsin K inhibitor odanacatib on osteoclastic bone resorption and vesicular trafficking. Bone 49: 623–635.
35. Littlewood-Evans A. Bilbe G. Bowler W. Farley D. Wlodarski B. Kokubo T. et al. (1997) The osteoclast-associated protease cathepsin K is expressed in human breast carcinoma. Cancer Res 57: 5386–5390.
36. Mandelin J. Hukkanen M. Li T. Korhonen M. Liljestrom M. Sillat T. et al. (2006) Human osteoblasts produce cathepsin K. Bone 38: 769–777.
37. Masarachia P. Pennypacker B. Pickarski M. Scott K. Wesolowski G. Smith S. et al. (2011) Odanacatib reduces bone turnover and increases bone mass in the lumbar spine of skeletally mature ovariectomized rhesus monkeys. J Bone Miner Res 27: 509–523.
38. Motyckova G. Fisher D. (2002) Pycnodysostosis: role and regulation of cathepsin K inosteoclast function and human disease. Curr Mol Med 2: 407–421.
39. Nakamura T. Shiraki M. Fukunaga M. Tomomitsu T. Uchida S. Fujimoto G. et al. (2012) A double-blind, randomized, dose-finding, phase 2 study of odanacatib, a potent cathepsin-K inhibitor, in Japanese patients with osteoporosis. In: Proceedings IOF-ECCEO12 European Congress on Osteoporosis and Osteoarthritis, Bordeaux, France, 21–24 March 2010.
40. Neer R. Arnaud C. Zanchetta J. Prince R. Gaich G. Reginster J. et al. (2001) Effect of parathyroid hormone (1–34) on fractures and bone mineral density in postmenopausal women with osteoporosis. N Engl J Med 344: 1434–1441.
41. Ochi Y. Yamada H. Mori H. Nakanishi Y. Nishikawa S. Kayasuga R. et al. (2011) Effects of ONO-5334, a novel orally-active inhibitor of cathepsin K, on bone metabolism. Bone 49: 1351–1356.
42. Pennypacker B. Le Duong T. Cusick T. Masarachia P. Gentile M. Gauthier J. et al. (2011) Cathepsin K inhibitors prevent bone loss in estrogen-deficient rabbits. J Bone Miner Res 26: 252–262.
43. Pennypacker B. Shea M. Liu Q. Masarachia P. Saftig P. Rodan S. et al. (2009) Bone density, strength, and formation in adult cathepsin K (-/-) mice. Bone 44: 199–207.
44. Podgorski I. (2009) Future of anticathepsin K drugs: dual therapy for skeletal disease and atherosclerosis? Future Med Chem 1: 21–34.
45. Reuters (2012) UPDATE 2-Merck bone drug shows clear benefits, trial halted. Reuters, 11 July. Available from: http://www.reuters.com/article/2012/07/12/merck-osteoporosis-idUSL2E8IBFKH20120712 [accessed 10 May 2013].
46. Rieman D. McClung H. Dodds R. Hwang S. Holmes M. James I. et al. (2001) Biosynthesis and processing of cathepsin K in cultured human osteoclasts. Bone 28: 282–289.
47. Rodan S. Duong L. (2008) Cathepsin K: a new molecular target for osteoporosis. IBMS BoneKey 5: 16–24.
48. Rood J. van Horn S. Drake F. Gowen M. Debouck C. (1997) Genomic organization and chromosome localization of the human cathepsin K gene (CTSK). Genomics 41: 169–176.
49. Rünger T. Adami S. Benhamou C. Czerwinski E. Farrerons J. Kendler D. et al. (2012) Morphea-like skin reactions in patients treated with the cathepsin K inhibitor balicatib. J Am Acad Dermatol 66: e89–e96
50. Schilling A. Mulhausen C. Lehmann W. Santer R. Schinke T. Rueger J. et al. (2007) High bone mineral density in pycnodysostotic patients with a novel mutation in the propeptide of cathepsin K. Osteoporos Int 18: 659–669.
51. Stoch S. Zajic S. Stone J. Miller D. van Dyck K. Gutierrez M. et al. (2009) Effect of the cathepsin K inhibitor odanacatib on bone resorption biomarkers in healthy postmenopausal women: two double-blind, randomized, placebo-controlled phase I studies. Clin Pharmacol Ther 86: 175–182.
52. Stroup G. Kumar S. Jerome C. (2009) Treatment with a potent cathepsin K inhibitor preserves cortical and trabecular bone mass in ovariectomized monkeys. Calcif Tissue Int 85: 344–355.
53. Subbiah V. Madsen V. Raymond A. Benjamin R. Ludwig J. (2010) Of mice and men: divergent risks of teriparatide-induced osteosarcoma. Osteoporos Int 21:1041–1045.
54. Sukhova G. Shi G. Simon D. Chapman H. Libby P. (1998) Expression of the elastolytic cathepsins S and K in human atheroma and regulation of their production in smooth muscle cells. J Clin Invest 102: 576–583.
55. Troen B. (2006) The regulation of cathepsin K gene expression. Ann N Y Acad Sci 1068: 165–172.
56. Vaaraniemi J. Halleen J. Kaarlonen K. Ylipahkala H. Alatalo S. Andersson G. et al. (2004) Intracellular machinery for matrix degradation in bone-resorbing osteoclasts. J Bone Miner Res 19: 1432–1440.
57. Vahle J. Sato M. Long G. Young J. Francis P. Engelhardt J. et al. (2002) Skeletal changes in rats given daily subcutaneous injections of recombinant human parathyroid hormone (1–34) for 2 years and relevance to human safety. Toxicol Pathol 30: 312–321.
58. Vasiljeva O. Reinheckel T. Peters C. Turk D. Turk V. Turk B. (2007) Emerging roles of cysteine cathepsins in disease and their potential as drug targets. Curr Pharm Des 13: 387–403.
59. Xiao Y. Junfeng H. Tianhong L. Lu W. Shulin C. Yu Z. et al. (2006) Cathepsin K in adipocyte differentiation and its potential role in the pathogenesis of obesity. J Clin Endocrinol Metab 91: 4520–4527.
60. Yamashita D. Yamashita D. Marquis R. Xie R. Nidamarthy S. Oh H. Jeong J. et al. (2006) Structure activity relationships of 5-, 6-, and 7-methyl-substituted azepan-3-one cathepsin K inhibitors. J Med Chem 49: 1597–1612.